Showing results (91-100 of 185) with videos related to

Sort By:
Pageof 19
Scientific Reports|July 15, 2021
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|November 10, 2020
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weightingAtsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 25, 2021
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis BNorio Itokawa, Masanori Atsukawa, Akihito Tsubota, et al.
Investigational New Drugs|June 8, 2019
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in JapanSadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, et al.
Scientific Reports|August 18, 2021
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective studyAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Reports (Hoboken, N.J.)|June 11, 2021
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experienceAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Investigational New Drugs|June 6, 2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2020
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysisMakoto Chuma, Haruki Uojima, Atsushi Hiraoka, et al.
European Journal of Gastroenterology & Hepatology|July 8, 2022
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
JCO Clinical Cancer Informatics|May 12, 2025
Prognostic Significance of the BALAD Serological Model in Systemic Therapies for Hepatocellular Carcinoma: A Personalized Approach to the Prediction of Survival BenefitHidenori Toyoda, Atsushi Hiraoka, Hironori Ochi, et al.
Pageof 19